期刊文献+

恶性肿瘤特异性生长因子在消化系统恶性肿瘤诊断中的价值 被引量:10

A research of stereotactic radiotherapy on nasopharyngeal carcinoma the recurrent and residual lesions after radiotherapy
暂未订购
导出
摘要 目的 了解恶性肿瘤特异性生长因子 (TSGF)在消化系统恶性肿瘤诊断及疗效判断中的价值。方法 对 39例消化系统恶性肿瘤患者治疗前后检测血清TSGF值 ,比较治疗前TSGF及CEA的阳性率 ,按年龄、肿瘤分化程度及有无转移分组比较术前TSGF值 ,按治疗方法分组配对比较治疗前后TSGF值的变化 ,分析TSGF值与性别、肿瘤分化程度及有无转移是否有相关关系。结果 在 39例消化系统恶性肿瘤诊断中 ,TSGF的阳性率为 74 4% ,而CEA的阳性率仅为 12 8% ,差异有极显著意义 (P <0 0 0 0 1) ;有远处转移组TSGF值明显高于无转移组 (P <0 0 0 1) ;TSGF值与远处转移呈明显正相关 (r=0 5 43,P <0 0 0 1) ;根治性手术治疗后TSGF值显著下降 (P <0 0 0 1)。结论 治疗前后检测TSGF值有助于消化系统恶性肿瘤的诊断及疗效判断 ,值得推广。 objective To evaluate the effect of stertotactic radiotherapy in the treatment of nasopheryngeal carcinoma the recurrent and residual lesions after radiotherapy.Methods 50 patient of residual and recurrent nasopharyngeal carcinoma were treated by stereotactic radiotherapy.Stage:I:0% Ⅱ:10.5%,Ⅲ69.2%,Ⅳ20.3%,Radiotherapy was delivered with the dose of DT 6800~7000c GY/7~8W.Chemotherapy schedule of PVF of POF for 2 cycles was given to stage Ⅲ~Ⅳ.Stereotactic radiotherapy was 600~800cGY per fration.once a week with total dose of 1800~2400cGY.Results The one year survival rate was 100%,The three year survival rate was 94%,CR 46%,GR 26%,PR 16% Conclusion The stereotactic radiotherapy is surperior to other methods in the treatmeat of residual and recurrent nasopharyngeal carcinoma.
出处 《贵州医药》 CAS 2001年第2期116-118,共3页 Guizhou Medical Journal
关键词 恶性肿瘤特异性生长因子 消化道恶性肿瘤 诊断价值 TSGF Malignant turnor digestive system Diagnosis velue
  • 相关文献

参考文献4

二级参考文献6

  • 1张世民,中华肿瘤杂志,1992年,14卷,143页
  • 2鞠新华,实用外科杂志,1991年,11卷,243页
  • 3许凯黎,肿瘤,1991年,11卷,86页
  • 4谢红,中华医学检验杂志,1990年,13卷,75页
  • 5Aniruddha Gangopadhyay,Donald A Lazure,Peter Thomas. Adhesion of colorectal carcinoma cells to the endothelium is mediated by cytokines from CEA stimulated Kupffer cells[J] 1998,Clinical and Experimental Metastasis(8):703~712
  • 6Dr. Antoni Castells M.D.,Xavier Bessa M.D.,Montserrat Daniels M.D.,Carlos Ascaso M.D.,Antonio M. Lacy M.D.,Juan Carlos García-Valdecasas M.D.,Laura Gargallo M.D.,Ferran Novell M.D.,Emiliano Astudillo M.D.,Xavier Filella M.D.,Josep M. Piqué M.D.. Value of postoperative surveillance after radical surgery for colorectal cancer[J] 1998,Diseases of the Colon &amp; Rectum(6):714~723

共引文献68

同被引文献56

  • 1宋万新,刘梅,陈军,李煜.血清TSGF检测对恶性肿瘤诊断及治疗的应用价值[J].河南肿瘤学杂志,2005,18(3):200-201. 被引量:7
  • 2孙燕 周际昌.临床肿瘤内科手册(第3版)[M].北京:人民卫生出版社,1996.98.
  • 3徐元斌 王德春 等.恶性肿瘤特异性生长因子(TSGF)测定及临床应用[J].福建医学检验,1996,1(3):118-118.
  • 4徐元斌.恶性肿瘤特异生长因子(TSGF)测定及临床应用[J].福建医学检验,1996,1(3):24-24.
  • 5华一兵 陈涛 马利民 等.胃肠道恶性肿瘤TSGF测定及其价值的初步评估[J].福建医药杂志,1999,21(6):82-83.
  • 6Baccala AA, Zhong H, Clift SM, Nelson WG, Marshall FF,Passe TJ, Gambill NB, Simons JW. Serum Vascular endothelial growth factor is a candidate biomarker of metastatic tumor response to ex vivo gene therapy of renal cell cancer.Urology 1998;51:327-332.
  • 7Mineta H, Miura K, Ogino T, Takebayashi S, Misawa K, Ueda Y, Suzuki I, Dictor M, Borg A, Wennerberg J. Prognostic value of Vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas. Br J Cancer 2000; 83:775-781.
  • 8Brockmann JG, St Nottberg H, Glodny B, Sprakel B, Senninger N. Analysis of serum CYFRA 21-1 concentrations in patients with esophageal cancer. Anticancer Res 2000;20:4899-4904.
  • 9Mealy K, Feely J, Reid I, McSweeney J, Walsh T, Hennessy TP.Tumour marker detection in oesophageal carcinoma. Eur J Surx, Oncol 1996;22:505-507.
  • 10Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H,Nabeya Y, Funami Y, Hayashi H, Gunji Y, Suzuki T,Kobayashi S, Ochiai T. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.Cancer 2000;89:1677-1683.

引证文献10

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部